William E Carson Iii

List of Publications by Year
in descending order

198	12,332	22153	31849
papers	citations	59 h-index	101 g-index

201	201	201	17692
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloidâ€Derived Suppressor Cells. Advanced Healthcare Materials, 2022, 11, e2101619.	7.6	11
2	The gut connection: Intestinal permeability as a pathway from breast cancer survivorsâ€™ relationship satisfaction to inflammation across treatment. Brain, Behavior, and Immunity, 2022, 100, 145-154.	4.1	4
3	Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Nonâ€“Small Cell Lung Cancer. JAMA Network Open, 2022, 5, e2221626.	5.9	11
4	Analysis of potential biomarkers of response to IL-12 therapy. Journal of Leukocyte Biology, 2022, 112, 557-567.	3.3	5
5	Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells. Clinical Lung Cancer, 2021, 22, e487-e497.	2.6	6
6	Breast cancer survivors' satisfying marriages predict better psychological and physical health: A longitudinal comparison of satisfied, dissatisfied, and unmarried women. Psycho-Oncology, 2021, 30, 699-707.	2.3	13
7	Observations on the use of Brutonâ€™s tyrosine kinase inhibitors in SAR-CoV-2 and cancer. Journal of Hematology and Oncology, 2021, 14, 15.	17.0	6
8	Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation. ACS Applied Nano Materials, 2021, 4, 3122-3139.	5.0	18
9	Brutonâ€™s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 2439-2451.	4.2	19
10	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood, 2021, 137, 3473-3483.	1.4	40
11	Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 435.e17-435.e22.	1.6	2
12	Loss of miR-1469 expression mediates melanoma cell migration and invasion. PLoS ONE, 2021, 16, e0256629.	2.5	2
13	Characterization of inflammatory changes in the breast cancer associated adipose tissue and comparison to the unaffected contralateral breast. Surgical Oncology, 2021, 39, 101659.	1.6	0
14	CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma. Frontiers in Cell and Developmental Biology, 2021, 9, 739816.	3.7	7
15	Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma. Frontiers in Immunology, 2021, 12, 740890.	4.8	15
16	Within-person changes in cancer-related distress predict breast cancer survivorsâ€™ inflammation across treatment. Psychoneuroendocrinology, 2020, 121, 104866.	2.7	10
17	Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma. Melanoma Research, 2020, 30, 455-464.	1.2	4
18	Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis. Scientific Reports, 2020, 10, 21824.	3.3	5

#	Article	IF	Citations
19	Reciprocal Signaling between Myeloid Derived Suppressor and Tumor Cells Enhances Cellular Motility and is Mediated by Structural Cues in the Microenvironment. Advanced Biology, 2020, 4, 2000049.	3.0	6
20	Guided migration analyses at the single-clone level uncover cellular targets of interest in tumor-associated myeloid-derived suppressor cell populations. Scientific Reports, 2020, 10, 1189.	3.3	7
21	Relationship satisfaction predicts lower stress and inflammation in breast cancer survivors: A longitudinal study of within-person and between-person effects. Psychoneuroendocrinology, 2020, 118, 104708.	2.7	21
22	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 120-131.	4.9	11
23	An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. Cancer Immunology, Immunotherapy, 2019, 68, 1379-1389.	4.2	26
24	Evidence for interaction of the NLRP3 inflammasome and Brutonâ€™s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta. OncoImmunology, 2019, 8, 1659704.	4.6	13
25	Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. , 2019, 7, 140.		100
26	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2019, 25, 4955-4965.	7.0	30
27	Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function. Scientific Reports, 2019, 9, 5068.	3.3	40
28	Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature. Hereditary Cancer in Clinical Practice, 2019, 17, 12.	1.5	31
29	A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma. Cancer Immunology, Immunotherapy, 2019, 68, 619-629.	4.2	7
30	Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy. Melanoma Research, 2019, 29, 491-500.	1.2	6
31	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	4.9	326
32	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. Cancer Immunology Research, 2018, 6, 671-684.	3.4	29
33	Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptorâ€“Mediated Natural Killer Cell Function. Clinical Cancer Research, 2018, 24, 1891-1904.	7.0	172
34	Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Research, 2018, 28, 390-397.	1.2	6
35	Concurrent phyllodes tumor, eccrine carcinoma, and multinodular goiter 20Âyears after radiotherapy for Hodgkin lymphoma. Clinical Case Reports (discontinued), 2018, 6, 2498-2503.	0.5	0
36	Unusual recurrence of breast cancer in a BRCAâ€variant patient after fat grafting. Clinical Case Reports (discontinued), 2018, 6, 2457-2462.	0.5	2

#	Article	IF	Citations
37	Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5534-5539.	7.1	73
38	Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. Journal of Surgical Oncology, 2018, 118, 501-509.	1.7	26
39	Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 909-920.	3.3	29
40	Phase III Randomized Study of 4 Weeks of High-Dose Interferon-Î±-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Groupâ€“American College of Radiology Imaging Network Cancer Research Group (E1697). Journal of Clinical Oncology, 2017, 35, 885-892.	1.6	42
41	Novel rodent model of breast cancer survival with persistent anxiety-like behavior and inflammation. Behavioural Brain Research, 2017, 330, 108-117.	2.2	27
42	Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 9629-9634.	7.1	16
43	Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy, 2017, 66, 1437-1447.	4.2	58
44	MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. Cancer Immunology Research, 2017, 5, 778-789.	3.4	12
45	Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Scientific Reports, 2017, 7, 15424.	3.3	68
46	Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor. OncoImmunology, 2017, 6, e1312045.	4.6	3
47	Classification of Indeterminate Melanocytic Lesions by MicroRNA Profiling. Annals of Surgical Oncology, 2017, 24, 347-354.	1.5	12
48	Trajectories of Stress, Depressive Symptoms, and Immunity in Cancer Survivors: Diagnosis to 5 Years. Clinical Cancer Research, 2017, 23, 52-61.	7.0	39
49	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clinical Cancer Research, 2017, 23, 489-502.	7.0	46
50	Plasma MicroRNA Levels Following Resection of Metastatic Melanoma. Bioinformatics and Biology Insights, 2017, 11, 117793221769483.	2.0	25
51	Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?. Journal of Clinical Oncology, 2017, 35, 149-156.	1.6	68
52	Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2017, 35, 2028-2036.	1.6	111
53	Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. Oncotarget, 2017, 8, 1481-1494.	1.8	26
54	MicroRNA profiling of patient plasma for clinical trials using bioinformatics and biostatistical approaches. OncoTargets and Therapy, 2016, Volume 9, 5931-5941.	2.0	4

#	Article	IF	Citations
55	A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma. Journal of Immunology, 2016, 197, 1489-1497.	0.8	26
56	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. Cell Reports, 2016, 16, 379-391.	6.4	100
57	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 450-473.	4.9	203
58	NCCN Guidelines Insights: Melanoma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 945-958.	4.9	76
59	Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions. Melanoma Research, 2016, 26, 329-337.	1.2	11
60	Fluorescent nanodiamonds and their use in biomedical research. , 2016, , .		3
61	A Progenitor Cell Expressing Transcription Factor RORÎ³t Generates All Human Innate Lymphoid Cell Subsets. Immunity, 2016, 44, 1140-1150.	14.3	153
62	A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-Î±-2b in patients with CEA-expressing carcinomas. Cancer Immunology, Immunotherapy, 2016, 65, 1353-1364.	4.2	31
63	Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors. Journal of Surgical Research, 2016, 205, 350-358.	1.6	18
64	Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. OncoImmunology, 2016, 5, e1214787.	4.6	25
65	A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. Molecular Cancer Therapeutics, 2016, 15, 2244-2250.	4.1	25
66	Interferon-Î³ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells. Journal of Biological Chemistry, 2016, 291, 25656-25666.	3.4	17
67	Structural characterization of NRAS isoform 5. Protein Science, 2016, 25, 1069-1074.	7.6	5
68	MicroRNA dysregulation in melanoma. Surgical Oncology, 2016, 25, 184-189.	1.6	47
69	Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte FcÎ³ Receptor (FcÎ³R) Function. Journal of Biological Chemistry, 2016, 291, 3043-3052.	3.4	61
70	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Cancer Research, 2016, 76, 2125-2136.	0.9	150
71	NK Cellâ€“Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. Cancer Immunology Research, 2016, 4, 323-336.	3.4	5
72	A Comprehensive Program for the Enhancement of Accrual to Clinical Trials. Annals of Surgical Oncology, 2016, 23, 2146-2152.	1.5	10

#	Article	IF	Citations
73	The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget, 2016, 7, 81172-81186.	1.8	9
74	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1337-1346.	4.9	23
75	Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12. BMC Medical Genomics, 2015, 8, 66.	1.5	15
76	Surgical management of ovarian carcinoma metastatic to the breast and axilla: A role for metastasectomy?. Journal of Surgical Oncology, 2015, 112, 581-584.	1.7	4
77	MiR-21 Enhances Melanoma Invasiveness via Inhibition of Tissue Inhibitor of Metalloproteinases 3 Expression: In Vivo Effects of MiR-21 Inhibitor. PLoS ONE, 2015, 10, e0115919.	2.5	83
78	Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel antiâ€tumor mechanisms of Cannabidiol in breast cancer. Molecular Oncology, 2015, 9, 906-919.	4.6	170
79	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. Cancer Immunology, Immunotherapy, 2015, 64, 149-159.	4.2	104
80	PTEN Is a Negative Regulator of NK Cell Cytolytic Function. Journal of Immunology, 2015, 194, 1832-1840.	0.8	37
81	RAGE Mediates S100A7-Induced Breast Cancer Growth and Metastasis by Modulating the Tumor Microenvironment. Cancer Research, 2015, 75, 974-985.	0.9	112
82	The Raf Kinase Inhibitor Sorafenib Inhibits JAKâ€“STAT Signal Transduction in Human Immune Cells. Journal of Immunology, 2015, 195, 1995-2005.	0.8	25
83	Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis. American Journal of Roentgenology, 2015, 205, W283-W293.	2.2	51
84	Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. ACS Nano, 2015, 9, 9731-9740.	14.6	220
85	ASCO 2015 update on melanoma. Surgical Oncology, 2015, 24, 363-365.	1.6	4
86	Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy. Surgical Oncology, 2015, 24, 353-358.	1.6	37
87	MicroRNA-3151 inactivates TP53 in BRAF -mutated human malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6744-51.	7.1	17
88	Tumor Infiltrating Lymphocytes â€“ The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. Journal of Carcinogenesis & Mutagenesis, 2014, 05, .	0.3	3
89	Cognitive problems among breast cancer survivors: loneliness enhances risk. Psycho-Oncology, 2014, 23, 1356-1364.	2.3	37
90	Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab. Radiology, 2014, 270, 425-434.	7.3	25

#	Article	IF	Citations
91	A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma. Journal of Immunotherapy, 2014, 37, 180-186.	2.4	16
92	A Phase I Trial of Bortezomib and Interferon-a-2b in Metastatic Melanoma. Journal of Immunotherapy, 2014, 37, 55-62.	2.4	14
93	Intronic miR-3151 Within BAALC Drives Leukemogenesis by Deregulating the TP53 Pathway. Science Signaling, 2014, 7, ra36.	3.6	18
94	Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival. Cancer Immunology Research, 2014, 2, 981-987.	3.4	9
95	Signaling pathways involved in MDSC regulation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 55-65.	7.4	152
96	Attachment anxiety is related to Epsteinâ€“Barr virus latency. Brain, Behavior, and Immunity, 2014, 41, 232-238.	4.1	46
97	NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4179-4184.	7.1	27
98	Social support predicts inflammation, pain, and depressive symptoms: Longitudinal relationships among breast cancer survivors. Psychoneuroendocrinology, 2014, 42, 38-44.	2.7	129
99	Melanoma, Version 4.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 621-629.	4.9	61
100	Pain, depression, and fatigue: Loneliness as a longitudinal risk factor.. Health Psychology, 2014, 33, 948-957.	1.6	234
101	Myeloid derived suppressor cells â€“ a new therapeutic target in the treatment of cancer. , 2013, 1, 10.		249
102	Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells. Veterinary Immunology and Immunopathology, 2013, 153, 249-259.	1.2	42
103	Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta. Arthritis Research and Therapy, 2013, 15, R191.	3.5	20
104	Heparin-binding EGF-like growth factor (HB-EGF) protects the intestines from radiation therapy-induced intestinal injury. Journal of Pediatric Surgery, 2013, 48, 1316-1322.	1.6	14
105	Review of S100A9 biology and its role in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 100-109.	7.4	114
106	A naonoporous cell-therapy device with controllable biodegradation for long-term drug release. Journal of Controlled Release, 2013, 165, 226-233.	9.9	14
107	Myeloid-derived suppressor cells in breast cancer. Breast Cancer Research and Treatment, 2013, 140, 13-21.	2.5	143
108	Betaâ€blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psycho-Oncology, 2013, 22, 1889-1894.	2.3	27

#	Article	IF	Citations
109	Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis. Journal of Clinical Oncology, 2013, 31, 30-38.	1.6	104
110	Melanoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 395-407.	4.9	134
111	Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology, 2012, 1, 1048-1060.	4.6	33
112	Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. OncoImmunology, 2012, 1, 1004-1016.	4.6	21
113	BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. Journal of Clinical Oncology, 2012, 30, 34-41.	1.6	172
114	Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab. Journal of Immunotherapy, 2012, 35, 367-373.	2.4	28
115	Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 366-400.	4.9	63
116	Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer.. Health Psychology, 2012, 31, 11-19.	1.6	42
117	Impact of breast cancer recurrence and cancer-specific stress on spouse health and immune function. Brain, Behavior, and Immunity, 2012, 26, 228-233.	4.1	21
118	Fatigue and herpesvirus latency in women newly diagnosed with breast cancer. Brain, Behavior, and Immunity, 2012, 26, 394-400.	4.1	35
119	Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Experimental Eye Research, 2012, 100, 26-31.	2.6	44
120	Î²-Adrenergic receptor mediated increases in activation and function of natural killer cells following repeated social disruption. Brain, Behavior, and Immunity, 2012, 26, 1226-1238.	4.1	35
121	Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cellâ€“activating cytokines. Surgery, 2012, 152, 431-440.	1.9	58
122	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	4.4	139
123	NK cell-based immunotherapy for treating cancer: will it be promising?. The Korean Journal of Hematology, 2011, 46, 3.	0.7	23
124	A Pilot Study of Bevacizumab and Interferon-Î±2b in Ocular Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 87-91.	1.3	19
125	A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma. Journal of Immunotherapy, 2011, 34, 509-515.	2.4	46
126	Use of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment. Journal of Controlled Release, 2011, 151, 239-245.	9.9	17

#	Article	IF	Citations
127	Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cellular Immunology, 2011, 270, 80-87.	3.0	86
128	Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunology, Immunotherapy, 2011, 60, 1269-1279.	4.2	134
129	Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells. Cancer Immunology, Immunotherapy, 2011, 60, 1281-1288.	4.2	21
130	Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice. Cancer Research, 2011, 71, 5101-5110.	0.9	170
131	IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-Î³ Production. Journal of Immunology, 2011, 186, 3401-3409.	0.8	95
132	Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer, 2010, 10, 142.	2.6	46
133	Reciprocal Regulation of Activating and Inhibitory FcÎ³ Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy. Clinical Cancer Research, 2010, 16, 2065-2075.	7.0	35
134	Interleukin-29 Binds to Melanoma Cells Inducing Jak-STAT Signal Transduction and Apoptosis. Molecular Cancer Therapeutics, 2010, 9, 510-520.	4.1	44
135	Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants. Clinical Cancer Research, 2010, 16, 3270-3278.	7.0	143
136	The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Molecular Cancer, 2010, 9, 165.	19.2	106
137	Folate-Immunoglobulin G as an Anticancer Therapeutic Antibody. Bioconjugate Chemistry, 2010, 21, 961-968.	3.6	17
138	Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy. Clinical Cancer Research, 2010, 16, 5917-5919.	7.0	1
139	A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Molecular Cancer Therapeutics, 2009, 8, 2983-2991.	4.1	100
140	A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Research and Treatment, 2009, 117, 83-89.	2.5	45
141	Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells. Cancer Immunology, Immunotherapy, 2009, 58, 2031-2037.	4.2	7
142	Immune Modulation with Interleukinâ€21. Annals of the New York Academy of Sciences, 2009, 1182, 39-46.	3.8	11
143	Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors. Journal of Clinical Oncology, 2009, 27, 5270-5277.	1.6	75
144	A Psychological Intervention Reduces Inflammatory Markers by Alleviating Depressive Symptoms: Secondary Analysis of a Randomized Controlled Trial. Psychosomatic Medicine, 2009, 71, 715-724.	2.0	105

#	Article	IF	Citations
145	Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay. Cancer Immunology, Immunotherapy, 2008, 57, 1137-1149.	4.2	11
146	Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. Cancer Immunology, Immunotherapy, 2008, 57, 1471-1481.	4.2	48
147	Delayed emotional recovery after taxaneâ€based chemotherapy. Cancer, 2008, 113, 638-647.	4.1	49
148	Psychologic intervention improves survival for breast cancer patients. Cancer, 2008, 113, 3450-3458.	4.1	408
149	Giant breast tumors: Surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature. World Journal of Surgical Oncology, 2008, 6, 117.	1.9	66
150	Biphasic anaphylactic reaction to blue dye during sentinel lymph node biopsy. World Journal of Surgical Oncology, 2008, 6, 79.	1.9	27
151	VEGF Secretion is Inhibited by Interferon-Alpha in Several Melanoma Cell Lines. Journal of Interferon and Cytokine Research, 2008, 28, 553-562.	1.2	28
152	IFN-Î± and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis. Cancer Research, 2008, 68, 8351-8360.	0.9	54
153	IFN-Î±-2bâ€“Induced Signal Transduction and Gene Regulation in Patient Peripheral Blood Mononuclear Cells Is Not Enhanced by a Dose Increase from 5 to 10 Megaunits/m2. Clinical Cancer Research, 2008, 14, 1438-1445.	7.0	15
154	Gene Expression Profiling Reveals Similarities between theIn vitroandIn vivoResponses of Immune Effector Cells to IFN-Î±. Clinical Cancer Research, 2008, 14, 5900-5906.	7.0	30
155	Colocalization of the IL-12 receptor and FcÎ³RIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-Î³. Blood, 2008, 111, 4173-4183.	1.4	72
156	IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood, 2008, 111, 4723-4730.	1.4	92
157	Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-Î± Compared with Immune Effector Cells. Clinical Cancer Research, 2007, 13, 5010-5019.	7.0	36
158	The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptorâ€“Positive Tumor Cells is Enhanced By Cytokines. Clinical Cancer Research, 2007, 13, 6419-6428.	7.0	131
159	Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain, Behavior, and Immunity, 2007, 21, 185-194.	4.1	59
160	Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain, Behavior, and Immunity, 2007, 21, 953-961.	4.1	159
161	Impaired Natural Killer Cell Lysis in Breast Cancer Patients with High Levels of Psychological Stress is Associated with Altered Expression of Killer Immunoglobin-Like Receptors. Journal of Surgical Research, 2007, 139, 36-44.	1.6	37
162	Current Immunotherapeutic Strategies in Breast Cancer. Surgical Oncology Clinics of North America, 2007, 16, 841-860.	1.5	5

#	Article	IF	Citations
163	Re-emphasizing the concept of adequacy of intraoperative assessment of the axillary sentinel lymph nodes for identifying nodal positivity during breast cancer surgery. World Journal of Surgical Oncology, 2007, 5, 18.	1.9	19
164	Immunotherapy comes of age: overview of the 21stAnnual Meeting and associated programs of the International Society for Biological Therapy of Cancer. Expert Opinion on Biological Therapy, 2007, 7, 419-422.	3.1	0
165	A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma. Annals of Surgical Oncology, 2007, 14, 2367-2376.	1.5	142
166	STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha. Cancer Immunology, Immunotherapy, 2007, 56, 1845-1852.	4.2	35
167	Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation. PLoS ONE, 2007, 2, e293.	2.5	98
168	Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy. Clinical Cancer Research, 2006, 12, 5850-5858.	7.0	31
169	FcÎ³R-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways. Blood, 2006, 108, 718-725.	1.4	30
170	Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. Journal of Immunotherapy, 2006, 29, 95-101.	2.4	25
171	Prospective Randomized Clinical Trial Comparing Intradermal, Intraparenchymal, and Subareolar Injection Routes for Sentinel Lymph Node Mapping and Biopsy in Breast Cancer. Annals of Surgical Oncology, 2006, 13, 1412-1421.	1.5	79
172	Interferon Î± and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects. Surgery, 2006, 140, 297-306.	1.9	10
173	Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets. Journal of Immunology, 2006, 177, 120-129.	0.8	109
174	Natural Killer Cells Produce T Cellâ€“Recruiting Chemokines in Response to Antibody-Coated Tumor Cells. Cancer Research, 2006, 66, 517-526.	0.9	132
175	Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. Blood, 2005, 105, 3011-3018.	1.4	76
176	Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunology, Immunotherapy, 2005, 54, 815-825.	4.2	29
177	Release of Biologically Functional Interferon-Alpha from a Nanochannel Delivery System. Biomedical Microdevices, 2005, 7, 71-79.	2.8	56
178	Phase I Study of the Sequential Combination of Interleukin-12 and Interferon Alfa-2b in Advanced Cancer: Evidence for Modulation of Interferon Signaling Pathways by Interleukin-12. Journal of Clinical Oncology, 2005, 23, 8835-8844.	1.6	26
179	Getting Melanoma Cells to Stimulate With Frequency. Journal of Clinical Oncology, 2005, 23, 8929-8931.	1.6	5
180	CpG-Containing Oligodeoxynucleotides Act through TLR9 to Enhance the NK Cell Cytokine Response to Antibody-Coated Tumor Cells. Journal of Immunology, 2005, 175, 1619-1627.	0.8	115

#	Article	IF	Citations
181	Src Homology 2â€“Containing Inositol 5â€²-Phosphatase 1 Negatively Regulates IFN-Î³ Production by Natural Killer Cells Stimulated with Antibody-Coated Tumor Cells and Interleukin-12. Cancer Research, 2005, 65, 9099-9107.	0.9	21
182	Multiparametric Flow Cytometric Analysis of Inter-Patient Variation in STAT1 Phosphorylation Following Interferon Alfa Immunotherapy. Journal of the National Cancer Institute, 2004, 96, 1331-1342.	6.3	72
183	Psychological, Behavioral, and Immune Changes After a Psychological Intervention: A Clinical Trial. Journal of Clinical Oncology, 2004, 22, 3570-3580.	1.6	351
184	Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment. Clinical Cancer Research, 2004, 10, 3401-3409.	7.0	88
185	A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies. Clinical Cancer Research, 2004, 10, 5027-5037.	7.0	108
186	Patterns of Recurrence After Sentinel Lymph Node Biopsy for Breast Cancer. Annals of Surgical Oncology, 2003, 10, 376-380.	1.5	57
187	A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses. Journal of Immunology, 2003, 170, 4242-4253.	0.8	70
188	The antitumor effects of IFN-Î± are abrogated in a STAT1-deficient mouse. Journal of Clinical Investigation, 2003, 112, 170-180.	8.2	105
189	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. Journal of Clinical Investigation, 2002, 110, 983-992.	8.2	142
190	IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. Journal of Clinical Investigation, 2002, 110, 983-992.	8.2	114
191	Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood, 2001, 97, 3146-3151.	1.4	1,201
192	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2 /neu-positive breast cancer cells. European Journal of Immunology, 2001, 31, 3016-3025.	2.9	141
193	Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2â€‰/â€‰neu-positive breast cancer cells. , 2001, 31, 3016.		3
194	CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin-2 and the c-kit ligand. European Journal of Immunology, 1997, 27, 354-360.	2.9	108
195	Interleukin 15: A Potential Player during the Innate Immune Response to Infection. Experimental Parasitology, 1996, 84, 291-294.	1.2	15
196	Receptors for Interleukin (IL)-10 and IL-6-type Cytokines Use Similar Signaling Mechanisms for Inducing Transcription through IL-6 Response Elements. Journal of Biological Chemistry, 1996, 271, 13968-13975.	3.4	84
197	Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma. Journal of Immunological Methods, 1991, 137, 225-235.	1.4	12
198	Rat Mitogen-Stimulated Lymphokine-Activated T Killer Cells. Journal of Immunotherapy, 1991, 10, 131-140.	2.4	8